Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kura Oncology (KURA) Cash & Equivalents: 2024-2025

Historic Cash & Equivalents for Kura Oncology (KURA) over the last 2 years, with Sep 2025 value amounting to $95.3 million.

  • Kura Oncology's Cash & Equivalents rose 92.58% to $95.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $95.3 million, marking a year-over-year increase of 92.58%. This contributed to the annual value of $224.5 million for FY2024, which is N/A change from last year.
  • According to the latest figures from Q3 2025, Kura Oncology's Cash & Equivalents is $95.3 million, which was up 16.28% from $81.9 million recorded in Q2 2025.
  • Kura Oncology's 5-year Cash & Equivalents high stood at $224.5 million for Q4 2024, and its period low was $41.5 million during Q1 2024.